Targeting the acetylation of Tau at residue 174 or restoring SIRT6 levels could mitigate Tau accumulation and potentially offer therapeutic strategies for Alzheimer’s disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.